| Literature DB >> 25671624 |
Xiaofei Guan1, Guoxin Fan1, Xinbo Wu1, Guangfei Gu1, Xin Gu1, Hailong Zhang1, Shisheng He1.
Abstract
A meta-analysis was conducted to assess alterations in measures of diffusion tensor imaging (DTI) in the patients of cervical spondylotic myelopathy (CSM), exploring the potential role of DTI as a diagnosis biomarker. A systematic search of all related studies written in English was conducted using PubMed, Web of Science, EMBASE, CINAHL, and Cochrane comparing CSM patients with healthy controls. Key details for each study regarding participants, imaging techniques, and results were extracted. DTI measurements, such as fractional anisotropy (FA), apparent diffusion coefficient (ADC), and mean diffusivity (MD) were pooled to calculate the effect size (ES) by fixed or random effects meta-analysis. 14 studies involving 479 CSM patients and 278 controls were identified. Meta-analysis of the most compressed levels (MCL) of CSM patients demonstrated that FA was significantly reduced (ES -1.52, 95% CI -1.87 to -1.16, P < 0.001) and ADC was significantly increased (ES 1.09, 95% CI 0.89 to 1.28, P < 0.001). In addition, a notable ES was found for lowered FA at C2-C3 for CSM vs. controls (ES -0.83, 95% CI -1.09 to -0.570, P < 0.001). Meta-regression analysis revealed that male ratio of CSM patients had a significant effect on reduction of FA at MCL (P = 0.03). The meta-analysis of DTI studies of CSM patients clearly demonstrated a significant FA reduction and ADC increase compared with healthy subjects. This result supports the use of DTI parameters in differentiating CSM patients from health subjects. Future researches are required to investigate the diagnosis performance of DTI in cervical spondylotic myelopathy.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25671624 PMCID: PMC4363894 DOI: 10.1371/journal.pone.0117707
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flow of identification of relevant studies.
Demographic and clinical characteristics of DTI studies of CSM in meta-analysis.
| Study | Year | Design | Level of evidence | Number (female) | Mean age, range (year) | Clinical assessment | Surgical treatment | ||
|---|---|---|---|---|---|---|---|---|---|
| CSM | HC | CSM | HC | ||||||
| Mamata | 2005 | Case-control | 3 | 7(3) | 11(6) | NA,26–82 | 37.7,30–48 | NA | |
| Facon | 2005 | Case-control | 3 | 7(3) | 11(3) | 48.2,30–76 | 36.7,NA | NA | |
| Xiangshui | 2010 | Case-control | 3 | 84(36) | 21(9) | 45,16–63 | 43,18–60 | NA | |
| Kim | 2010 | Case-control | 3 | 8(2) | 14(NA) | 59.5,48–78 | 34,NA | NA | |
| Kang | 2011 | Case-control | 3 | 11(5) | 10(6) | 67.2, NA | 33.4, NA | NA | |
| Lee | 2011 | Case-control | 3 | 21(7) | 26(7) | 49.6,22–67 | 49.6,22–67 | mJOA | ✓ |
| Budzik | 2011 | Case-control | 3 | 20(10) | 15(7) | 57.3,34–78 | 54.8,35–73 | Self questionnaire | |
| Song | 2011 | Case-control | 3 | 53(25) | 20(6) | 56,47–71 | 55,46–67 | NA | |
| Uda | 2013 | Case-control | 3 | 26(11) | 30(15) | 59.4,41–82 | 44.2,20–72 | NA | |
| Wen | 2013 | Case-control | 3 | 7(4) | 15(NA) | 56,45–67 | 42,36–48 | mJOA | |
| Wen | 2014 | Case-control | 3 | 45(19) | 20(10) | 64,43–86 | 52,41–62 | mJOA | ✓ |
| Banaszek | 2014 | Case-control | 3 | 132(78) | 25(14) | 53.58,18–76 | 45.78,27–80 | NA | |
| Cui | 2014 | Case-control | 3 | 23(8) | 20(NA) | 59,NA | 46,NA | mJOA | |
| Rajasekaran | 2014 | Case-control | 3 | 35(32) | 40(20) | 48,NA | 38,NA | Nurick | |
CSM, cervical spondylotic myelopathy; HC, healthy control; mJOA, modified Japanese Orthopedic Association score; NA, not available
Technical details of DTI studies on ALS in meta-analysis.
| Study | Year | DTI measures | Scanner make | Field-str. | DTI dir. | Voxel size(mm) | DTI proc. | ROI placement | FOV (mm) | b (mm2/s) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FA | ADC | MD | ||||||||||
| Mamata | 2005 | ✓ | ✓ | General Electric | 1.5 T | NA | NA | NA | Sagittal | 220*110 | 1000 | |
| Facon | 2005 | ✓ | ✓ | NA | 1.5 T | 6 | 1.4*1.4 | DPTools | Sagittal | 179*179 | 500 | |
| Xiangshui | 2010 | ✓ | ✓ | General Electric | 3.0 T | 15 | NA | GE Functool | Axial | 270*270 | 1000 | |
| Kim | 2010 | Siemens | 3.0 T | 12 | 1.5*1.5 | home-made software | Sagittal | 160*40 | 500 | |||
| Kang | 2011 | ✓ | ✓ | Siemens | 1.5 T | NA | NA | Syngo software | Axial | 140*140 | 1000 | |
| Lee | 2011 | ✓ | ✓ | Philips Achieva | 3.0 T | 15 | 1.95*1.95 | NA | Axial | 250*224 | 600 | |
| Budzik | 2011 | ✓ | ✓ | Philips Achieva | 1.5 T | 25 | 1.56*1.56 | NA | Sagittal | 200*200 | 900 | |
| Song | 2011 | ✓ | ✓ | Philips Gyroscan | 1.5 T | 6 | NA | NA | Axial | 230*230 | 400 | |
| Uda | 2013 | ✓ | ✓ | Philips Achieva | 3.0 T | 15 | 1.5*1.5 | NA | Axial | 240*240 | 1000 | |
| Wen | 2013 | ✓ | Philips Achieva | 3.0 T | 15 | 0.63*0.64 | Diffusion Toolkit | Axial | 80*80 | 600 | ||
| Wen | 2014 | ✓ | Philips Achieva | 3.0 T | 15 | 1.0*1.26 | DTI Studio software | Axial | 80*80 | 600 | ||
| Banaszek | 2014 | ✓ | ✓ | General Electric | 1.5 T | 15 | 1.6*1.6 | GE Functool | Axial | 160*160 | 1000 | |
| Cui | 2014 | ✓ | ✓ | Philips Achieva | 3.0 T | 15 | 0.63*0.63 | Diffusion Toolkit | Axial | 80*36 | 600 | |
| Rajasekaran | 2014 | ✓ | ✓ | Siemens | 1.5 T | 12 | 0.86*0.86 | NA | Axial | 220*220 | 500 | |
DTI, diffusion tensor imaging; FA, fractional anisotropy; ADC, apparent diffusion coefficient; MD, mean diffusivity; ROI, region of interest; T, Tesla; FOV, field of voxel; NA, not available
Quality assessment of studies according to Newcastle-Ottawa Scale.
| Study | Year | Selection | Comparability | Exposure | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| S1 | S2 | S3 | S4 | C1 | C2 | E1 | E2 | E3 | |||
| Mamata | 2005 | * | * | * | * | * | * | * | * | * | 9 |
| Facon | 2005 | * | * | * | * | - | - | * | * | * | 7 |
| Xiangshui | 2010 | * | * | * | * | * | - | * | * | * | 8 |
| Kim | 2010 | * | * | * | * | - | - | * | * | * | 7 |
| Kang | 2011 | * | * | * | * | * | - | * | * | * | 8 |
| Lee | 2011 | * | * | * | * | * | * | * | * | * | 9 |
| Budzik | 2011 | * | * | * | * | * | * | * | * | * | 9 |
| Song | 2011 | * | * | * | * | * | * | * | * | * | 9 |
| Uda | 2013 | * | * | * | * | * | - | * | * | * | 8 |
| Wen | 2013 | * | * | * | * | * | - | * | * | * | 8 |
| Wen | 2014 | * | * | * | * | * | - | * | * | * | 8 |
| Banaszek | 2014 | * | * | * | * | * | - | * | * | * | 8 |
| Cui | 2014 | * | * | * | * | * | - | * | * | * | 8 |
| Rajasekaran | 2014 | * | * | * | * | - | - | * | * | * | 7 |
S1: Selection1-is the case definition adequate; S2: Selection2-representativeness of the cases; S3: Selection3-selection of controls; S4: Selection4-definition of controls. C1: Comparability1-comparability of controls for most important factor; C2: Comparability2-comparability of controls for other factors. E1: Exposure1-ascertainment of exposure; E2: Exposure2-same method of ascertainment for cases and controls; E3: Exposure3-non-response rate.
Fig 2Forest plot of Standardized mean differences (SMD) for FA at most compressed level between CSM patients and healthy controls.
FA was significantly reduced in CSM patients. CI indicates confidence interval.
Fig 3Forest plot of Standardized mean differences (SMD) for ADC at most compressed level between CSM patients and healthy controls.
ADC was significantly increased in CSM patients. CI indicates confidence interval.
Fig 4Forest plot of Standardized mean differences (SMD) for FA at C2-C3 level between CSM patients and healthy controls.
FA was significantly reduced in CSM patients. CI indicates confidence interval.
Fig 5The relationship between effect size for FA and male ratio of CSM patients.